Loading...
•
Sep 30, 2022
Myomo Q3 2022 Earnings Report
Reported strong authorizations and orders and record backlog.
Key Takeaways
Myomo reported third quarter revenue of $4.0 million, an 8% sequential increase, driven by a higher average selling price. The company received 130 authorizations and orders, resulting in a record-high backlog of 184 units. Gross margin was 66.5%, and the net loss was $2.8 million, or $0.40 per share.
Product revenue was $4.0 million, up 8% sequentially.
Revenue units were 87, up 9% sequentially.
MyoPro orders and insurance authorizations were received for 130 patients, up 27% sequentially.
Backlog was a record 184 units, up 13% sequentially.
Forward Guidance
The company expects modest sequential product revenue growth in the fourth quarter and anticipates entering 2023 with a larger pipeline, positioning the company for stronger product revenue growth.
Positive Outlook
- Expect to be able to report modest sequential product revenue growth in the fourth quarter
- Expect to enter 2023 with a much larger pipeline than we entered 2022
- Positioning the Company for stronger product revenue growth in 2023
Challenges Ahead
- Growing the pipeline will be seasonally challenging in the fourth quarter due to competition from holiday and election advertising
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...